CIRM Funded Clinical Trials

A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas

Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$11,999,984
Trial Sponsor:
Beckman Research Institute of City of Hope
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A